Insider buying last 90 days
No open-market insider purchases were filed for CNMD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CNMD insider filing, plotted on the chart in Gekko.Open CNMD in Gekko
NYSE: CNMD
CONMED (CNMD) Stock Analysis & Forecast
Oct 12 close
$45.36+0.94 (+2.1%)
Gekko Brief
AI summaryOct 12 closeThis week's commentary on CONMED centers on analyst activity and valuation debate rather than new corporate news. Argus lowered its target price for CNMD to $47.00, while a separate report cites an average "Reduce" rating from eight research firms with an average target of $41.40. Other coverage flags the stock as undervalued after a 6.0% drop, alongside broader mentions of upgrades and downgrades from firms including Piper Sandler, Wells Fargo, BMO Capital, and B of A Securities.
CNMD closed at $45.36, up 2.1%, sitting between its 50-day average of $47.99 and 200-day average of $41.07. The GekkoIndex reads 60.5, placing the stock in the Accumulation zone. Price remains 29.5% below Gekko Fair Value of $64.34. Over the past six months the stock has returned 17.9%, though the one-month return is -2%.
CONMED next reports earnings on 28 October 2026 after close, 16 days away and inside a typical 20-trading-day holding window; the prior quarter saw an EPS beat of $1.38 versus $1.11 estimated, with a 6.2% reaction, and the company has beaten estimates in 6 of the last 8 quarters. No insider, Congress, or unusual options activity appears in the current window. Seasonally, the next 20 trading days have averaged a 7.2% gain over 5 years, positive in 3 of them. Consensus analyst sentiment includes 5 hold and 1 sell rating among 6 firms, with a consensus target of $45.50.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
CONMED price vs fair value
Close $45.36200-day averageGekko Fair Value $64.34
CONMED quick facts
- Market cap
- $1.36B
- P/E ratio
- 25.4
- Forward P/E
- 27.2
- EPS, TTM
- $1.74
- Revenue, TTM
- $1.37B
- Profit margin
- 4.1%
- Dividend yield
- —
- Beta
- 0.94
- Volume
- 515,218 avg 386,625
- 1-year return
- −0.1%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.4%
- 50-day average
- $47.99
- 200-day average
- $41.07
- Next earnings
- Oct 28 after close
- Shares outstanding
- 29.95M
CONMED swing-trade checklist
CONMED scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $45.36 sits between the 50-day ($47.99) and 200-day ($41.07) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.5, Accumulation
Reading 60.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
29.5% below
Price is 29.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 16 days
Reports on Oct 28, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.2% on average
From this point in the calendar, the next 20 trading days averaged +7.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
CONMED stock chart and price history
CONMED closed at $45.36 on Oct 12, 2026, −0.1% over the past year, inside a 52-week range of $31.44 to $53.66.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.0%
- 3 months
- +8.6%
- 6 months
- +17.9%
- 1 year
- −0.1%
The full CNMD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CNMD in Gekko
Follow CONMED through every session
Put CNMD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CNMD in GekkoFree for 7 days. No credit card required.
About CONMED
CONMED makes surgical instruments and equipment used across a range of operations, selling its devices worldwide. The company is known for its orthopedic products, including soft tissue fixation systems and suture anchors designed to help surgeons repair injuries during minimally invasive sports medicine procedures, sold under brand names such as Hall, CONMED Linvatec, Concept, and Shutt.
Beyond orthopedics, CONMED produces general surgical equipment covering insufflation, smoke evacuation, electrosurgery, and endomechanical tools. It also makes diagnostic and therapeutic instruments for gastroenterology and for treating biliary conditions, along with cardiac monitoring items such as ECG and EEG electrodes and defibrillation pads. Its customers include hospitals and surgical centers, reached both through direct sales and through specialized medical distributors.
CONMED was founded in 1970 and is headquartered in Largo, Florida. Its shares are listed on the NYSE under the ticker CNMD.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- conmed.com
CONMED GekkoIndex: the smart money zone
CONMED’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, up 3.7 points over five sessions.
60.5Accumulation
Up 3.7 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 62 | +0.2% | +2.7% | ||
| Accumulation (current zone) | 328 | 0.0% | +0.6% | ||
| Neutral | 282 | −0.9% | −4.9% | ||
| Distribution | 9 | Too few readings yet | |||
| Selling | 1 | Too few readings yet | |||
Average CNMD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CNMD price, zone by zone.Track CNMD in Gekko
Is CONMED stock overvalued? Gekko Fair Value
CONMED trades 29.5% below Gekko Fair Value of $64.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what CONMED shares are worth, recalculated every trading day.
$64.34
Gekko Fair Value, Oct 9, 2026
29.5% Undervalued
At the end of Aug 2026 the price was 30.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open CNMD in Gekko
CONMED insider and Congress trading
No open-market insider purchases were filed for CONMED, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CNMD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CNMD, plotted on the chart in Gekko.Open CNMD in Gekko
Buybacks
CONMED has been buying back its own shares.
- Latest authorization
- $150.0M, Jan 12, 2026
- Bought back, quarter ended Jun 30, 2026
- $6.20M
- As a share of market cap
- 0.46%
From company filings.
CONMED earnings: next date and track record
CONMED reports on Oct 28, 2026, after the close (16 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected after the close, 16 days away
- EPS estimate
- $1.00
- Revenue estimate
- $336.3M
6 of 8reports beat the EPS estimate
±5.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- CONMED reported Q2 2026 net sales of $343.5 million, up 0.3% as-reported but down 0.5% on constant currency basis. Organic net sales grew 6% year-over-year, exceeding guidance. Adjusted diluted EPS of $1.38 rose 20% year-over-year, boosted by a $0.21 tariff refund benefit. General Surgery organic sales grew 5.3%, driven by AirSeal and Buffalo Filter, with mid-single digit U.S. growth and high-single digit international growth.
- Guidance
- Management updated 2026 financial guidance in the earnings press release. Organic growth exceeded the high end of prior expectations. Excluding the $0.21 tariff refund benefit, underlying EPS still beat guidance by approximately $0.03.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $1.38 est $1.11 | $343.5M est $337.6M | +6.2% |
| Apr 29, 2026 | $0.89 est $0.82 | $317.0M est $310.6M | −0.4% |
| Jan 28, 2026 | $0.54 est $1.26 | $373.2M est $366.9M | −5.7% |
| Nov 5, 2025 | $0.09 est $0.88 | $337.9M est $366.9M | −3.3% |
| Jul 30, 2025 | $1.15 est $1.13 | $342.3M est $334.6M | +1.7% |
| Apr 30, 2025 | $0.95 est $0.81 | $321.3M est $313.4M | +11.8% |
| Feb 5, 2025 | $1.34 est $1.20 | $347.9M est $341.0M | −7.6% |
| Oct 30, 2024 | $1.05 est $1.00 | $316.7M est $318.1M | +5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CONMED stock forecast and analyst price targets
Analysts’ average 12-month price target for CONMED is $45.50, +0.3% from the last close, from 6 firms rating the stock in the last 90 days.
$45.50consensus 12-month target, +0.3% from the last close
Now $45.36Avg $45.50
Low $45High $46
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Jul 30 | J.P. Morgan | $45 | −0.8% |
| Jul 30 | Wells Fargo | $46 | +1.4% |
| Jul 30 | Piper Sandler | $45 | −0.8% |
| Jul 30 | Needham | — | — |
| Jul 30 | Bank of America Securities | — | — |
+0.6%average 20-day move after past Accumulation readings
+7.2%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CONMED seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, CONMED averaged +7.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.6% | 4 of 5 |
| Next 10 trading days | +2.5% | 3 of 5 |
| Next 15 trading days | +3.1% | 4 of 5 |
| Next 20 trading days | +7.2% | 3 of 5 |
| Next 30 trading days | +6.5% | 5 of 5 |
For scale, CNMD’s typical 20-trading-day move in either direction is about 7.4%.
CONMED market cap and key statistics
CONMED’s market cap is $1.36B, with a P/E ratio of 25.4 and revenue of $1.37B over the last twelve months.
Valuation
- Market cap
- $1.36B
- P/E ratio
- 25.4
- Forward P/E
- 27.2
- EPS, TTM
- $1.74
- Gekko Fair Value
- $64.34
Trading
- Volume
- 515,218
- Avg volume, 20 days
- 386,625
- 52-week high
- $53.66
- 52-week low
- $31.44
- Shares outstanding
- 29.95M
Financials
- Revenue, TTM
- $1.37B
- Profit margin
- 4.1%
- Return on equity
- 5.5%
- Quarterly earnings growth, YoY
- +11.2%
Risk and income
- Beta
- 0.94
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.4%
CONMED stock news this week
Coverage of CONMED this week reads positive: 2 positive, 2 neutral and 1 negative headlines.
- CONMED Corporation (CNMD) Stock forecastsYahoo Finance Singapore, Oct 11
- Understanding Momentum Shifts in (CNMD)Stock Traders Daily, Oct 9
- CONMED Corporation (NYSE:CNMD) Stock Has Average Price Target of $41.40MarketBeat, Oct 9
- Conmed Corp (EC8.SG) Analyst insights, Price targets and RecommendationsYahoo Finance UK, Oct 8
- Is Conmed Corp (CNMD) a Bargain After 6.0% Drop? GF Value Says UndervaluedGuruFocus, Oct 6
- Conmed Corp (EC8.SG) Analyst Insights, Price Targets & RecommendationsYahoo! Finance Canada, Oct 6
CONMED peers
CONMED’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
CONMED stock FAQ
What is CONMED’s market cap?
CONMED’s market cap is $1.36B at the Oct 12, 2026 close of $45.36, with 29.95M shares outstanding. The shares trade on a P/E ratio of 25.4.
What is the CONMED stock forecast?
The consensus analyst 12-month price target for CONMED is $45.50, +0.3% from the last close. Of the 6 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is CONMED stock overvalued or undervalued?
On Gekko’s estimate CONMED is undervalued: the Oct 12, 2026 close of $45.36 is 29.5% below Gekko Fair Value of $64.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CONMED report earnings next?
CONMED is expected to report on Oct 28, 2026, after the market closes (16 days away). Analysts expect earnings of $1.00 per share on revenue of $336.3M. CONMED beat the earnings estimate in 6 of its last 8 reports, moving 5.3% on average across the report.
What is CONMED’s 52-week high and low?
CONMED’s 52-week high is $53.66 and its 52-week low is $31.44; it closed at $45.36 on Oct 12, 2026, −0.1% over the past year. Over the last five years the shares peaked at $159.11 on Nov 5, 2021.
Is CONMED stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CONMED the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.